Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - upadacitinibum - retardtablette - upadacitinibum 15 mg per upadacitinibum hemihydricum, cellulosum microcristallinum, hypromellosum, mannitolum, acido tartaricum, silice colloidalis anhydrica, magnesio stearas, poli(alcole vinylicus), macrogolum 3350, talco, e 171, e 172, per compresso haze. - selettiva immunosoppressore - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopica - altri preparati dermatologici - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 50 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.814 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 1.365 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 100 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.629 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 2.73 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant può essere usato in monoterapia o in combinazione con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 e 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - compresse rivestite con film - tofacitinibum 5 mg tofacitinibi citras, excipiens pro compresso haze. - selettiva immunosoppressore - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tofacitinibum - compresse rivestite con film - tofacitinibum 10 mg a tofacitinibi citras, colore.: e 132, e 133, excipiens pro compresso haze. - selettiva immunosoppressore - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinib maleato - agenti per dermatiti, esclusi i corticosteroidi - cani - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.